AstraZeneca to discontinue Epanova trial, expects $100 million writedownBusiness, Mixed Dyslipidaemia, Mixed Dyslipidemia, R&DAstraZeneca said on Monday the company will discontinue a late-stage trial for the heart disease drug Epanova to treat patients with mixed dyslipidemia and expects a $100 million writedown to hit its core profit in the fourth quarter. Read more January 13, 2020/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2020-01-13 02:55:082020-01-13 12:15:06AstraZeneca to discontinue Epanova trial, expects $100 million writedown